Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00299962 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for Pleural Malignancies
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00299962: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT00299962 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00299962, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This Phase I study will evaluate the safety of two doses of BG00001 at different doses and intervals. Eligible subjects will have: * malignant pleural mesothelioma, or * pleural effusions who have progressed through at least one prior therapy or have refused therapy BG00001 is given twice through a catheter in the pleural space.
Interventions
- BIOLOGICAL Adenoviral-mediated Interferon-beta
- BIOLOGICAL SCH 721015
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00299962
The ClinicalTrials.gov registry entry for NCT00299962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adenoviral-mediated Interferon-beta is the first listed.
NCT00299962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00299962 about?
NCT00299962 is a clinical study titled "Gene Therapy for Pleural Malignancies". This Phase I study will evaluate the safety of two doses of BG00001 at different doses and intervals. Eligible subjects will have: * malignant pleural mesothelioma, or * pleural effusions who have progressed through at least one prior therapy or have refused therapy BG00001 is given twice through ...
What is the current status of trial NCT00299962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2006-03. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00299962?
The interventions under investigation include: Adenoviral-mediated Interferon-beta (BIOLOGICAL), SCH 721015 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00299962?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.